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ABSTRACT
Genomic structural variations (SVs) are pervasive in
many types of cancers. Characterizing their under-
lying mechanisms and potential molecular conse-
quences is crucial for understanding the basic biol-
ogy of tumorigenesis. Here, we engineered a local
assembly-based algorithm (laSV) that detects SVs
with high accuracy from paired-end high-throughput
genomic sequencing data and pinpoints their break-
points at single base-pair resolution. By applying
laSV to 97 tumor-normal paired genomic sequencing
datasets across six cancer types produced by The
Cancer Genome Atlas Research Network, we discov-
ered that non-allelic homologous recombination is
the primary mechanism for generating somatic SVs
in acute myeloid leukemia. This finding contrasts
with results for the other five types of solid tumors, in
which non-homologous end joining and microhomol-
ogy end joining are the predominant mechanisms.
We also found that the genes recursively mutated by
single nucleotide alterations differed from the genes
recursively mutated by SVs, suggesting that these
two types of genetic alterations play different roles
during cancer progression. We further characterized
how the gene structures of the oncogene JAK1 and
the tumor suppressors KDM6A and RB1 are affected
by somatic SVs and discussed the potential func-
tional implications of intergenic SVs.
INTRODUCTION
Genomic structural variations (SVs) such as deletions, in-
sertions, inversions, translocations and tandemduplications
are an important class of genetic variations that underlies
genomic diversity in a population (1). A deep and com-
prehensive understanding of the formation mechanism, ge-
nomic distribution and functional impacts of SVs is crucial
for studying complex diseases such as cancer.
Performing a comprehensive survey of different SV for-
mation mechanisms and their relative contributions across
different cancer types is difficult because it entails precise
characterization of the sequences across the breakpoints.
Despite extensive efforts, accurately detecting SVs with a
high resolution still remains a challenge. Most existing SV
discovery methods take advantage of three types of signals
that are indicative of SVs between the reference genome and
the sample genome: changes in the coverage of read pile-
up, suggesting copy number alterations (read depth); dis-
cordant read pairs with a distance or orientation between
the two reads that is inconsistent with the reference genome
(read pair); and reads that can be split into parts that align
to discontiguous loci in the reference genome (split reads)
(2–8). It is algorithmically challenging to integrate informa-
tion from these sources; furthermore, reads (or parts of a
read) that can be aligned to multiple loci in the reference
genomemay result in spurious SV calls. Somemethods such
as TIGRA (9) try to pinpoint the breakpoints of predicted
SVs by assembling reads mapped to the loci. This approach
does not avoid the mapping ambiguities since both the SV
predictions and the read selection for assembly are based on
aligning short reads to the reference genome. A potential
alternative is to perform a reference-free de novo assembly
of the sequencing reads first and then compare the contigs
with the reference genome. However, conventional de novo
assembly methods are not designed for the purpose of SV
discovery, especially for samples with a high degree of het-
erogeneity such as tumor samples. These tools assume that
all the reads originate from a single underlying genome and
therefore only detect homozygous SVs (10). In this report,
we described a de novo local assembly-based SV discovery
algorithm, designated laSV, which is able to pinpoint SV
breakpoints at a single-nucleotide resolution and estimate
the allele frequencies of the detected SVs in the sample.
Double-stranded breaks (DSBs) in genomic DNA are
detrimental to the cell, and several DSB repair pathways
have therefore evolved to protect the cell from such catas-
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trophic events. These pathways do not repair DSBs per-
fectly and erroneous repairs are believed to be an impor-
tant source of SVs (11), especially in cancers. Homologous
recombination (HR) is the mechanism most widely used by
the cell to repair DSBs, and it requires long stretches of ho-
mologous sequences at the breakpoints. When HR occurs
between non-allelic regions with high sequence similarity,
termed non-allelic homologous recombination (NAHR),
structural alterations may ensue (12–14). Mutations in
genes that are key components of the HR pathway, such as
BRCA1 and BRCA2, are observed in many types of cancers
and deemed themajor driving force of genomic instability in
these cancers. Nonhomologous end joining (NHEJ), how-
ever, does not require sequence homology and often gen-
erates very short deletions or insertions at the breakpoint.
Key players in this pathway include XRCC5/6 and TP53
(15,16). An alternative pathway, known as microhomology-
mediated end joining (MMEJ), plays an active role in some
cancers (17,18). MMEJ relies on relatively short stretches
of homologous sequence (≤25 bp) at the breakpoint (19).
The molecular details of this pathway are much less well
understood compared with NAHR and NHEJ, although it
is known to share the initial end resection step with NAHR
(19). In another DNA replication-associated repair mecha-
nism, known as fork stalling and template switching (FoS-
TeS), it has been proposed that when a replication fork is
stalled during replication, the polymerase is able to switch
to a nearby locus and use it as the template to continue
replicating, which often results in complex rearrangements
(18,20).
Applying laSV to six cancer types, we discovered that
in acute myeloid leukemia (AML), NAHR is the major
mechanism for generating somatic SVs, while in the other
five types of solid tumor, NHEJ and MMEJ are the pre-
dominant forces underlying somatic SVs. We further ob-
served that such a preference for DSB repair pathway uti-
lization could be ascribed to the differential expression of
several key genes in the HR pathway among the evaluated
cancer types. Moreover, we analyzed genes that were af-
fected by somatic SVs and to our surprise we found that the
genes frequently mutated by SVs tended to differ from the
genes frequently mutated by single nucleotide alterations,
which suggests different roles for the two types of muta-
tions during cancer development. We also described in de-
tail examples of complex genomic rearrangements and in-
tragenic SVs disrupting known oncogenes and tumor sup-
pressors. Finally we characterized the somatic SVs in in-
tergenic regions and discussed the potential functional im-
plications of SVs that overlap with genomic regulatory ele-
ments. The laSV package is freely available at https://github.
com/JialiUMassWengLab/laSV/tree/master.
MATERIALS AND METHODS
Detection of putative SVs via de novo local assembly
The construction and storage of a de Bruijn graph is
adopted from the CORTEX algorithm (21). After the con-
struction of the de Bruijn graph from raw reads, laSV maps
the reads to the branch sequences using the BWA MEM
algorithm and identifies ‘connected’ branches as those cov-
ered by the same read or the same read pair (Supplemen-
tary Figure S1). The connections of branches are stored as a
hash table in the RAM and used for extending contigs dur-
ing traversing. Next, the de Bruijn graph is traversed in a
breadth-first manner to output the ‘maximal unambiguous
contigs’ (MUCs). MUCs are defined as the longest contigs
that contain only the connected branches (Supplementary
Figure S2). These MUCs are then mapped to the reference
genome using BWA MEM, which performs a local align-
ment. Contig segments that can be mapped to multiple loci
in the reference genome are discarded because laSV cannot
determine their origin unequivocally. Contigs that can be
split-mapped to discontiguous loci of the reference genome
are classified as discordant. Discordant contigs are indica-
tive of putative SVs and are retained for further analysis.
Genotyping and estimation of SV allele frequencies
laSV further validates the putative SVs by mapping the raw
reads to sequences that represent both the putative SV alle-
les derived from the assembled contigs and the correspond-
ing alleles in the reference genome using the BWA aln al-
gorithm. SV and reference alleles are prepared by extend-
ing 500 bp from the breakpoints in both directions. SV calls
with fewer than four read pairs mapping to the variant al-
lele are most likely false positives and are discarded. Based
on the number of reads mapped to the variant allele and
the corresponding reference allele, laSV estimates the fre-
quency of the variant allele using the formula F = CVCV+CR ,
with effective coverages CV = VlV and CR =
R1+R2
2lR
, where V,
R1 and R2 represent the number of SV-supporting reads,
the number of reads supporting reference locus 1 and the
number of reads supporting reference locus 2, respectively
(Supplementary Figure S3). Effective lengths lV and lR are
given by lV =
1000∑
i=h
λ(i )(i − h) and lR =
1000∑
i=0
λ(i )i , where h is
the homologous sequence length and λ (i ) is the proportion
of reads with fragment size i in the library (22).
After performing de novo SV discovery in the cancer
genomes, we genotyped all of the putative SVs in the
matched normal genomes. The SVs present in the cancer
genomes with a≥ 10% allele frequency that were supported
by ≥4 read pairs and were absent from the matched normal
genomes were considered somatic SVs.
Validation of NA12878 SVs using long-read sequencing
datasets
We validated the SV calls of laSV in an individual with Eu-
ropean ancestry using the long-read sequencing datasets for
the same individual provided byMoleculo and PacBio. The
datasets were downloaded from the 1000 Genomes Project
FTP site:
ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/phase3/
integrated sv map/supporting/NA12878/moleculo/, and
ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/phase3/
integrated sv map/supporting/NA12878/pacbio/.
An SV was considered validated if there are 2 PacBio
reads or 1 Moleculo read that supported the same type of
SV with a breakpoint within 6 nt of that identified by laSV.
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Simulated datasets for comparing SV detection algorithms
To compare the performance of laSV with several other
methods, we generated simulated datasets each with 100
deletions, inversions and tandem duplications randomly in-
serted across human chromosome 9 using the SV simulation
tool RSVSim (23). Paired-end Illumina sequencing reads at
30× coverage with the mean and variance of the fragment
size 400 and 50 bp respectively were then simulated using
the pIRS software (24). The process was repeated for 100
times to produce 10 000 deletions, inversions and tandem
duplications in total.
Classification of SV mechanisms
Our inference regarding the SV formation mechanism is
based on the homology length, defined as the length of
the homologous sequence between the two breakpoint loci
(Supplementary Figure S4). We define breakpoints with
a homology length ≤2 and ≥−10 (a negative homology
length indicates insertion at the breakpoint) as being gener-
ated by NHEJ, those with a homology length >2 and ≤25
as being generated by MMEJ, and those with a homology
length>25 as being generated byNAHR. Breakpoints with
>10 nt insertion at the breakpoint are classified as non-
template insertions.
Detection of complex rearrangements
We used breakpoint graphs, as described by Pevzner (25),
for the detection of complex rearrangements. Briefly, each
node in the graph represents a genomic position, and two
nodes are connected by a ‘breakpoint edge’ if there is an SV
bringing the two genomic positions together. Two nodes are
connected by an ‘adjacency edge’ if the distance between
the two genomic positions is shorter than 100 Kb, and the
weight of the edge is defined as the genomic distance be-
tween the two positions. An alternating path in the graph is
defined as a path consisting of adjacency edges and break-
point edges in an alternating fashion. A shortest alternating
path in the graph that contains at least two breakpoint edges
represents a potential complex rearrangement. The shortest
alternating path between all pairs of nodes can be computed
using a variant of the Dijkstra algorithm, as described by
Brown (26).
Whole-genome sequencing and RNA-seq datasets
All of the whole-genome sequencing and RNA-seq datasets
used in this study were produced by The Cancer Genome
Atlas (TCGA) Research Network. The full list of samples
used is listed in Supplementary Table S1. The FASTQ raw
sequence reads of genomic DNA were downloaded from
CGHub (https://cghub.ucsc.edu/) and transcriptomeRNA-
seq data were obtained from the Data Portal of TCGA
(https://tcga-data.nci.nih.gov/tcga/).
Analysis of intergenic SVs
Intergenic SVs (SVs that do not overlap with any genes)
in BRCA, CESC, GBM, AML and UCEC were over-
lapped with the ENCODE DNaseI Hypersensitivity Uni-
form Peaks from the cell lines MCF-7, Helas3, Gliobla,
Figure 1. A schematic representation of the workflow of laSV.
K562 and Ishikawa, respectively. For enrichment simulation
analysis, 20 000 random SV sets were generated for each of
the five types of cancer, with each random set exhibiting ex-
actly the same number of SVs and same SV length distri-
bution as the observed set. Each random SV set was over-
lapped with the DNase HS peaks in the corresponding cell
type and empirical P-values were computed as the fraction
of random sets showing more overlap than the observed SV
set.
RESULTS
Detection of SVs
The overall workflow of laSV is depicted in Figure 1. It
first uses raw sequence reads in the FASTQ format as input
and performs reference-free local assembly using de Bruijn
graphs to generate contigs. Next, it aligns those contigs to
the reference genome and detects all discordant alignments,
i.e. different parts of the same contig mapped to discon-
tiguous loci of the reference genome, which are indicative
of putative SVs. Finally it maps the raw sequence reads
to both the variant allele sequence (obtained from the as-
sembled contigs) and the corresponding reference allele se-
quence and estimates the allele frequencies of the putative
SVs based on the ratio of variant-supporting reads over
reference-supporting reads. This approach naturally inte-
grates read-pair and split-read information, and by produc-
ing contigs that are much longer than raw sequence reads,
it avoids some mapping ambiguities and, hence, achieves
higher accuracy. We use a local assembly approach to avoid
aggressively pruning the de Bruijn graphs, preserving true
SVs present at low allele frequencies in the sample. More-
over, the reference-free assembly makes it possible to cap-
ture novel sequences that are not present in the reference
genome.
To evaluate the accuracy of our method, we ran laSV
on a high-coverage whole-genomeDNA sequencing dataset
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from an individual of European descent (NA12878) pro-
duced by the 1000Genomes Project and validated its results
by comparing the calls withMoleculo and PacBio long-read
sequencing datasets for the same individual. Among the
SVs predicted by laSV with allele frequencies above 10%,
91.54% (1687 out of 1843) of the deletions and 94.93% (262
out of 276) of the non-template insertions were supported
by the long-read sequencing datasets, suggesting that most
of the laSV predictions were correct.
We also compared laSV and other SV detection methods
CREST (6), pindel (7), delly (5) and lumpy (8) on both simu-
lated datasets (see ‘Materials andMethods’ section) and the
NA12878 sequencing dataset. On simulated datasets, laSV
achieved 99.20, 99.46, 99.51% precision rates and 83.18,
85.98, 81.34% recall rates for deletions, inversions and tan-
dem duplications, respectively. Compared with the other
methods, laSV has high specificity while maintaining good
sensitivity (Supplementary Figure S5). On the NA12878
dataset, laSV outperforms the other methods in specificity
(Supplementary Figure S6). These results show that laSV is
able to make reliable predictions for various SV types.
We applied laSV to 97 cancer-normal paired high-
coverage whole-genome sequencing datasets across six can-
cer types: uterine corpus endometrial carcinoma (UCEC),
glioblastomamultiforme (GBM) (27,28), sarcoma (SARC),
cervical squamous cell carcinoma and endocervical adeno-
carcinoma (CESC), breast invasive carcinoma (BRCA) (29)
and AML (30), produced by The Cancer Genome Atlas
(TCGA) Research Network (Supplementary Table S1). We
identified somatic SVs as those that were present in the can-
cer sample but absent in the normal tissue of the corre-
sponding individual. A total of 35 396 somatic SVs were
detected, and we observed a high degree of heterogeneity in
terms of the total number of somatic SVs, the composition
of different SV types and the possible contributions of dif-
ferent SVmechanisms across samples, even within the same
cancer type (Figure 2). An analysis of the SV length distri-
bution reveals that most of the somatic SVs are very short
(a few hundred base pairs) deletions and inversions (Sup-
plementary Figure S7), which are possibly the product of
error-prone DNA repairs and may have limited phenotypic
impact.
We asked whether the SVs in CESC were due to human
papillomavirus (HPV), which is a major cause for CESC.
We aligned all the contigs assembled fromCESC samples to
the genomes of all 175HPV strains downloaded fromPaVE
(http://pave.niaid.nih.gov/) using the BLAT algorithm (31).
None of the contigs indicative of SVs could be aligned to the
HPV genomes, suggesting that the SVs we identified were
not caused by HPV.
A survey of molecular mechanisms underlying somatic SVs
Because laSV has the capability to pinpoint breakpoints
with a single-nucleotide resolution, we were able to infer
the molecular mechanisms underlying the somatic SVs we
detected based on the sequence homology at breakpoints
(Figure 2B). In all five of the solid tumor types we ana-
lyzed, NHEJ and MMEJ appear to be the predominant
forces driving somatic SVs, which is consistent with pre-
vious reports (32,33). Surprisingly, in AML, most somatic
SVs show long stretches of homologous sequences across
breakpoints and are probably the result of NAHR. To en-
sure that this difference is not an artifact due to the choice
of homology length cutoffs for classifying the three mech-
anisms, we plotted the distributions of sequence homology
lengths at SV breakpoints across all of the samples we ana-
lyzed (Figure 2C). Despite substantial heterogeneity among
samples within the same cancer type, AML samples gener-
ally exhibit longer sequence homology at breakpoints than
the other cancer types (P-values are 1.46e-4, 1.20e-3, 8.69e-
3, 2.36e-5 and 0.0153 versus BRCA, CESC, GBM, SARC
and UCEC, respectively; Wilcoxon rank sum test).
What might be the reasons for such a differential pref-
erence for DSB repair pathways among cancer types? We
found that for a third of the known genes in the HR path-
way (6/18), the expression level is significantly higher in
AML than in all the other cancer types (q-value < 0.01;
Supplementary Figure S9). The genes that are more abun-
dantly expressed in AML include BRCA2, FAM175A and
BRIP1, which encode RAD51 mediators, proteins crucial
for recruiting RAD51 to the damaged sites and initiating
the HR pathway upon DNA damage (12). Perhaps these
more highly expressed HR genes increase the activity of the
HR pathway in AML and lead to a higher proportion of
SVs produced by NAHR than in the other cancers.
Identification of complex genomic rearrangements
Complex genomic rearrangements are defined as SVs that
are formed in a single event and involve multiple break-
points. One class of replication-based mechanisms capa-
ble of generating such complex rearrangements is replica-
tion fork stalling and template switching (FoSTes) andmore
generally microhomology-mediated break-induced replica-
tion (MMBIR) (20). Another mechanism is chromothrip-
sis, massive chromosomal rearrangements that occur dur-
ing a single catastrophic event within a localized genomic
region (34). To identify potential complex rearrangements,
we developed a graph-based algorithm to connect break-
points that are proximal to each other (see ‘Materials and
Methods’ section for more details).
Figure 3A shows an example of complex rearrangement
likely due to MMBIR. In the gene body of MEGF8, there
is a 749 bp deletion and in its place is a segment of 5584 bp
that includes the 3′ portion of PPR19 and the 5′ portion
of TMEM145, two genes upstream of MEGF8. The two
breakpoints exhibit 3 and 1-bp homology, respectively. This
rearrangement effectively creates two fused genes,MEGF8–
PPR19 with exons 1–19 of MEGF8 and TMEM145–
MEGF8 with exons 20–42 ofMEGF8. RNA-seq data from
the same individual indicates that the expression level of ex-
ons 1–19 of MEGF8 is 1.24-fold higher than exons 20–42
ofMEGF8 (Figure 3A). The TMEM145–MEGF8 chimeric
transcript likely undergoes nonsense-mediated decay due to
a premature stop codon caused by the fusion and the reads
mapping to exons 20–42 ofMEGF8 are from the wild-type
copy of theMEGF8 gene in the sister chromosome.
In addition, we noticed that in some of the samples, there
are a large number of breakpoints concentrated within lo-
calized genomic regions. For instance, in one SARC sam-
ple, the vast majority of breakpoints fall within four nar-
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Figure 2. An overview of the SVs across all of the samples we analyzed. The distribution of (A) different types of SVs, (B) different breakpoint mechanisms
and (C) breakpoint homology sequence lengths across all 97 samples. The evaluated cancer types are indicated at the bottom of each panel. For CESC,
two different scales are used because three of the samples contain many more SVs than the remaining samples. (D) Expression levels of three key genes of
the HR pathway across different cancer types. Samples within the same cancer type are ranked by the total number of somatic SVs in descending order
in (A) and (B) and are ranked by the median homology sequence length in descending order in (C). TPM is transcripts per million, a means of gene
expression quantification used by the RSEM algorithm, in which the total number of transcripts in a cell is normalized to one million. RNA-seq data were
not available for the GBM samples.
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Figure 3. Examples of complex SVs. (A) An example of anMMBIR. Boxes (I) and (II) show the two breakpoint sequences. The characters in bold indicate
homologous sequences. (B) Two examples of chromothripsis.
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row genomic regions in chromosomes 1, 5, 12 and 14 (Fig-
ure 3B; left). There are alsomany novel adjacencies connect-
ing fragments of these four regions, suggesting extensive re-
arrangements possibly as a result of faulty DNA repairs in
response to chromothripsis. Another SARC sample shows
similar patterns with different genomic loci being affected
(Figure 3B; right).
Somatic SVs that overlap protein-coding genes
In the samples we studied, there were a total of 17 184
protein-coding genes overlapping at least one SV in at least
one sample (Supplementary Table S2). Most of those SVs
probably do not confer a growth advantage to the tumor
cells carrying them and, hence, are so-called ‘passenger mu-
tations’. However, there was a significant enrichment of
known oncogenes and tumor suppressors (35) (P-value =
0.013; hypergeometric test) among the genes affected by so-
matic SVs. Furthermore, when we restricted our analysis to
somatic SVs present with a 20% or higher allele frequencies,
the enrichment was more significant (P-value = 6.5e-3; hy-
pergeometric test), suggesting that SVs having phenotypic
consequences are more likely to cause a cancer subclone to
be selected and increase in frequency.
When we performed gene ontology analysis on genes that
are affected by SVs in multiple samples for each of the
six cancer types (Supplementary Figure S10), we observed
enrichment for processes such as immune responses, kera-
tinization, metallopeptidase-related processes and cell–cell
adhesion. Mutations in genes belonging to these biological
processes and pathways are unlikely to cause tumorigene-
sis. Instead, they might confer a growth advantage on tu-
mor cells and allow them to evade the immune system and
metastasize.
Three of the cancer types we analyzed (BRCA,GBMand
AML) have been extensively studied before by the TCGA
consortium (29–30,27). Whole-exome sequencing was per-
formed on hundreds of samples for each of these three can-
cer types to identify recurrently mutated genes. We com-
pared the lists of genes showing recurrent single-nucleotide
alterations (SNAs) and indels with the genes that we found
to be affected by SVs and asked whether the same genes
tended to harbor both SNAs/indels and SVs. In BRCA,
the overlap between genes showing recurrent point muta-
tions and genes affected by SVs was statistically signifi-
cant (P-value = 0.0184, hypergeometric test). In GBM and
AML, however, there was no significant overlap between re-
currently point-mutated and SV-mutated genes (P-value =
0.378 and 0.093 for GBM and AML, respectively), suggest-
ing that SNAs/indels and SVs may play different roles dur-
ing cancer development.
For all of the genes harboring SVs or SNAs in a given
cancer type (point-mutation data are not available for
SARC), we correlated the number of samples where SV-
induced mutations occurred with the number of samples
where point mutations occurred. We observed negative cor-
relations for all five cancer types, with Pearson correla-
tion coefficients being−0.537,−0.785,−0.713,−0.293 and
−0.697 (all P-values < 1e-100) for UCEC, GBM, CESC,
BRCA and AML, respectively, indicating that genes show
recurrent point mutations are less likely to harbor SV mu-
tations (Figure 4A).
To test whether this negative correlation was due to the
decreased power of detecting SNAs in deleted regions, we
assessed the relative impact of deletions in each cancer type.
Since all SNAs are in coding regions (CDS), we compared
the total length of deletedCDSwith the length of duplicated
CDS in each cancer type (Supplementary Table S3). Our re-
sults revealed no strong bias toward deletion over duplica-
tion and therefore the aforementioned negative correlations
are unlikely to be the result of compromised SNA detection
power due to deletions. Furthermore, since the breakpoints
of the SVs fall predominantly in intergenic and intronic re-
gions far away from CDS, it is also highly unlikely that the
negative correlations are caused by the effect of SNAs on
SV detection power.
The tumor suppressor KDM6A encodes a lysine-specific
demethylase that catalyzes the demethylation of tri- and di-
methylated H3K27. Missense and nonsense mutations in
this gene have been reported in multiple cancer types (36).
In one of the CESC samples, laSV detected a 148 495 bp
deletion that eliminates exons 3–28 ofKDM6A (Figure 4B).
This deletion leads to a much shortened transcript, which
if translated, encodes a nonfunctional protein because the
JmjC catalytic domain is deleted. Based on RNA-seq data
from the same individual, we observed 48 reads that map
across the exon 2–exon 29 junction, indicating that the mu-
tated version of the KDM6A gene was indeed transcribed.
The oncogene JAK1 encodes a non-receptor tyrosine ki-
nase whose hyperactivity has been implicated in multiple
cancer types, including breast cancer, colorectal cancer and
lung cancer (37,38). We observed a 22 471 bp tandem du-
plication that includes exons 6–12 in one of the BRCA sam-
ples (Figure 4C). At the protein level, this duplication leads
to an extra copy of a portion of the FERM domain, the
entire SH2 domain, and the SH2-pseudokinase linker. Re-
cent biochemical studies have shown that the FERM do-
main and the SH2 domain of JAK family proteins are cru-
cial for binding to the cytoplasmic region of the cytokine re-
ceptors (39,40). Perhaps the duplication increases the affin-
ity with which JAK1 binds to the cytokine receptor or shifts
the relative position of the kinase domainwith respect to the
cytokine receptor, disrupting proper regulation.
In both of the above examples, the mutated genes are still
translated in-frame. In other cases, SVs may also cause a
frameshift and, thus, grossly alter the amino acid sequences
of the protein product.RB1 is a negative regulator of the cell
cycle and was the first discovered tumor suppressor (41). In
one of the BRCA samples, we observed a tandem duplica-
tion that included exons 7–12 of the RB1 gene. This results
in a frameshift that leads to a premature stop codon (Fig-
ure 4D). In the same individual, we observed a six-fold de-
crease inRB1 expression in the tumor tissue compared with
the nearby normal tissue. The premature stop codon is lo-
cated 2077 nt upstream of the last exon–exon junction and
may have triggered nonsense-mediated decay, leading to the
decreased RB1 level.
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Figure 4. The impact of somatic SVs on protein-coding genes. (A) Comparison of genes frequently affected by point mutations with those frequently
affected by SVs. Purple bars indicate the percentage of samples in which the gene carries SNAs while orange bars indicate the percentage of samples in
which the gene carries SVs. The purple genes are the ones most frequently affected by SNAs within each cancer type; orange genes are the ones mostly
frequently affected by SVs. (B) A deletion within the tumor suppressor KSDM6A. The black dashed line indicates the exon–exon junction. The orange
sequences are representative RNA-seq reads that map across the junction. (C) A tandem duplication within the oncogene JAK1. (D) Amino acid sequences
of the wild-type and duplicated versions of RB1. The red asterisks indicate stop codons.
Some intergenic SVs may impact genomic regulation
SVs that do not overlap any gene are usually ignored due
to the difficulty of evaluating their possible effects. For five
of the six cancer types we analyzed (except SARC) we were
able to find DNaseI sequencing data produced by the EN-
CODE consortium on cell types corresponding to the same
tissue. We then intersected the intergenic SVs with DNase
hypersensitive sites (DHSs) in the corresponding cell type.
Overall, a background level of 1.10% (356/32455) inter-
genic SVs overlapped with DNase hypersensitive regions.
Nevertheless, DHS-overlapping SVs have higher allele fre-
quencies than the non-overlapping SVs (P-value = 3.73e-4,
WilcoxonRank Sum test, Supplementary Figure S11), indi-
cating that DHS-overlapping SVs are more likely to confer
a growth advantage.
BCL9 is an oncogene that encodes an important com-
ponent of the Wnt pathway. BCL9 interacts with -catenin
to enhance its transcriptional activity and is implicated in
several types of cancer (42,43). In one of the BRCA sam-
ples, we observed a 22 847-bp duplication upstream of the
BCL9 gene that overlaps with two DHSs in MCF-7 cells
(Figure 5). One of the DHSs is bound by the transcription
factors E2F1, CTCF, RAD21 andMAX.Moreover, the Pol
II ChIA-PETdata indicate that there is a chromatin interac-
tion between the DHS and the promoter of the BCL9 gene,
which suggests that the DHS may regulate BCL9 transcrip-
tion. Indeed, we observed a 63.52% increase in BCL9 ex-
pression in the tumor sample compared with the matched
normal sample. It is likely that the duplication of the regu-
latory DHS leads to an elevated expression level of BCL9.
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Figure 5. An example of somatic SV affecting intergenic gene regulatory elements. In one of the BRCA samples a tandem duplication spans a DNase
hypersensitive site containing regulatory elements of oncogene BCL9.
DISCUSSION
Cancer is a group of complex diseases driven by various
genetic and epigenetic alterations. Previous surveys on ge-
netic alterations in cancer have mostly focused on single-
nucleotide mutations in protein-coding sequences, fusion
transcripts and copy number alterations of large genomic
segments (35). In this article, we reported a novel algorithm,
laSV, that is capable of detecting genomic SVs across a wide
spectrum of sizes from highly heterogeneous tumor samples
and pinpointing their breakpoints at a single-nucleotide res-
olution.Applying this algorithm to 97 high-coveragewhole-
genome sequencing datasets across six cancer types, we ob-
served several interesting phenomena.
Because laSV supports nucleotide-resolution delineation
of SV breakpoints, we examined the prevalence of differ-
ent breakpoint formationmechanisms across all of the sam-
ples that we analyzed. To our knowledge, there have been
two studies conducted thus far that have comprehensively
surveyed breakpoint formation mechanisms across multi-
ple cancer types (32,33). Both studies included only solid
tumors and concluded that most breakpoints exhibit lit-
tle or no homology and were therefore probably formed
via NHEJ or MMEJ. We observed similar patterns in the
five types of solid tumors that we analyzed. In AML,
however, most of the breakpoints showed homologous se-
quences much longer than those needed for NHEJ and
MMEJ, suggesting that NAHR is the predominant mech-
anism of breakpoint formation. Such a preference for dif-
ferent breakpoint formationmechanismsmight provide im-
portant insight into the course of evolution taken by differ-
ent cancer types and have implications for the development
of cancer type-specific treatments.
At present laSV employs BWA to align assembled contigs
to the reference and predict SV breakpoints. There are other
methods, such as YAHA (44) and AGE (45), that specialize
in aligning long sequences and detecting potential break-
points. In the future it would be interesting to explore how
laSV performs using these software for contigs alignment.
In addition to reflecting the confidence level of the SV calls,
the SV allele frequency computed by laSV could also be use-
ful in some other applications, such as distinguishing driver
mutations from passenger mutations since driver mutations
tend to occur early on during the tumor development and
therefore be present in most of the cells in the tissue. Fur-
thermore, when samples from different stages of the tumor
development or from different metastasized sites are avail-
able, it would be informative to compare the SV allele fre-
quencies across those samples as they may reveal how the
cancer progressed and adapted to new metastasized loca-
tions.
The fact that genes that show recurrent SNAs do not
appear to be preferentially mutated by SVs is noteworthy.
Considering that the spontaneous mutation rate for point
mutations is much higher than for SVs (46), we hypoth-
esize that tumorigenesis is often initiated by point muta-
tions and that most SVs occur later during cancer develop-
ment, whenDNA repair mechanisms are compromised. Be-
cause additional SV mutations in a gene already disrupted
by cancer-causing point mutations rarely enhance the can-
cer phenotype, they are unlikely to be selected for in the tu-
mor tissues. The observation that genes that are recurrently
affected by SVs are enriched for pathways such as cytoskele-
ton metabolism, immune response and cell–cell adhesion,
which are unlikely to cause uncontrolled cell proliferation
but may contribute to the migration, immune defense eva-
sion and metastasis of cancer cells, further supports our hy-
pothesis. The characterization of SVs in cancer lags behind
that of SNAs/indels because whole-genome sequencing is
more costly than exome sequencing. More cancer genomes
need to be sequenced to more accurately identify genes re-
currently affected by SVmutations for various cancer types.
Our results indicated that in addition to point mutations,
gains/losses of large genomic segments and transcript fu-
sions, intragenic SVs can also have a significant impact on
the expression levels and products of protein-coding genes,
as demonstrated by the examples of KDM6A, JAK1 and
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RB1. Therefore, laSV, with its ability to accurately detect
more subtle SVs, will be a valuable tool for future surveys
of genetic alterations in cancers.
Previous reports on cancer research have mostly focused
on genetic alterations within or including CDS. A recent
study suggests that a large fraction of the non-coding por-
tion of the human genomemay contain regulatory elements
(47). We found that some of the SVs in non-CDS regions
overlap with DHSs and might have regulatory functions.
The example of BCL9 that we described demonstrates how
SV discovery in the non-CDS regions can, when consid-
ered in conjunction with the rich information accumulated
by the ENCODE consortium, shed new light on regulatory
alterations in cancer. With our rapidly expanding knowl-
edge regarding the various regulatory elements in the hu-
man genome, further studies will be carried out to interro-
gate the roles of non-coding regulatory regions in cancer.
The accurate identification of more subtle SVs and the pre-
cise determination of their breakpoints will be crucial for
the success of such investigations.
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